Although public speaking clearly isn't his strong point, SB seems very positive in regards to becoming a producer in the next 12 months. That would put RLE well ahead of it's peers.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%